Walter A. Kostich
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Migraine and Headache Studies, Pain Mechanisms and Treatments, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Neuropeptides and Animal Physiology
Most-Cited Works
- → Molecular Identification and Analysis of a Novel Human Corticotropin-Releasing Factor (CRF) Receptor: The CRF2γ Receptor(1998)256 cited
- → Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain(2016)119 cited
- → Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine(2012)86 cited
- → From the prodromal stage of multiple sclerosis to disease prevention(2022)79 cited
- → High‐Affinity Agonist Binding Correlates with Efficacy (Intrinsic Activity) at the Human Serotonin 5‐HT2A and 5‐HT2C Receptors: Evidence Favoring the Ternary Complex and Two‐State Models of Agonist Action(1999)58 cited
- → Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine(2012)42 cited
- → Expression of zfh‐4, a new member of the zinc finger‐homeodomain family, in developing brain and muscle(1995)38 cited
- → Pathways to cures for multiple sclerosis: A research roadmap(2022)35 cited
- → Immunohistochemical visualization of corticotropin‐releasing factor type 1 (CRF1) receptors in monkey brain(2004)32 cited
- → Discovery of (S)-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain(2022)27 cited